The Sabin Vaaccine Institute Product Development Partnership's hookworm vaccine has been shown to be safe in Brazilian clinical trials.

"Researchers from the Sabin Vaccine Institute Product Development Partnership found the vaccine was well tolerated by 102 healthy volunteers and blood tests showed that they developed an immune response. None of them had ever been exposed to hookworm before.
David Diemert, Sabin’s director of clinical trials, tells SciDev.Net: 'A vaccine able to induce long-lasting immunity, which could be incorporated into existing vaccination programmes in countries like Brazil, would provide a sustainable solution to the problem of hookworm.'"